lewy body disease

Summary

Summary: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)

Top Publications

  1. ncbi Cortical Lewy body pathology in the diagnosis of dementia
    A J Harding
    Prince of Wales Medical Research Institute, Sydney, NSW, Australia
    Acta Neuropathol 102:355-63. 2001
  2. ncbi Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies
    Michael L Kramer
    Prion and Dementia Research Unit, Institute of Neuropathology, University of Goettingen, 37075 Goettingen, Germany
    J Neurosci 27:1405-10. 2007
  3. pmc Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study
    Jennifer Molano
    Mayo Clinic, Rochester, MN 55905, USA
    Brain 133:540-56. 2010
  4. ncbi Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium
    I G McKeith
    Institute for Ageing and Health, University of Newcastle upon Tyne, UK
    Neurology 65:1863-72. 2005
  5. ncbi Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease
    John P Anderson
    Elan Pharmaceuticals, South San Francisco, California 94080, USA
    J Biol Chem 281:29739-52. 2006
  6. ncbi Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains
    Kazuhiro Imamura
    Department of Neurology, Okazaki City Hospital, 3 1 Goshoai, Kouryuuji cho, 444 8553, Okazaki, Aichi, Japan
    Acta Neuropathol 109:141-50. 2005
  7. pmc Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein
    Dora Games
    Neotope Biosciences, South San Francisco, California, USA
    Am J Pathol 182:940-53. 2013
  8. pmc Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy
    Leslie Crews
    Department of Pathology, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 5:e9313. 2010
  9. pmc Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases
    Brian Spencer
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0624, USA
    J Neurosci 29:13578-88. 2009
  10. ncbi DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers
    C F Lippa
    Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Neurology 68:812-9. 2007

Detail Information

Publications276 found, 100 shown here

  1. ncbi Cortical Lewy body pathology in the diagnosis of dementia
    A J Harding
    Prince of Wales Medical Research Institute, Sydney, NSW, Australia
    Acta Neuropathol 102:355-63. 2001
    ..These results suggest that dual pathologies cause DLB, and high densities of parahippocampal Lewy bodies indicate dementia regardless of additional pathologies...
  2. ncbi Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies
    Michael L Kramer
    Prion and Dementia Research Unit, Institute of Neuropathology, University of Goettingen, 37075 Goettingen, Germany
    J Neurosci 27:1405-10. 2007
    ..This concept may also be valid for Parkinson's disease...
  3. pmc Mild cognitive impairment associated with limbic and neocortical Lewy body disease: a clinicopathological study
    Jennifer Molano
    Mayo Clinic, Rochester, MN 55905, USA
    Brain 133:540-56. 2010
    There are little data on the relationship between Lewy body disease and mild cognitive impairment syndromes...
  4. ncbi Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium
    I G McKeith
    Institute for Ageing and Health, University of Newcastle upon Tyne, UK
    Neurology 65:1863-72. 2005
    ....
  5. ncbi Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease
    John P Anderson
    Elan Pharmaceuticals, South San Francisco, California 94080, USA
    J Biol Chem 281:29739-52. 2006
    ....
  6. ncbi Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains
    Kazuhiro Imamura
    Department of Neurology, Okazaki City Hospital, 3 1 Goshoai, Kouryuuji cho, 444 8553, Okazaki, Aichi, Japan
    Acta Neuropathol 109:141-50. 2005
    ....
  7. pmc Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein
    Dora Games
    Neotope Biosciences, South San Francisco, California, USA
    Am J Pathol 182:940-53. 2013
    ..These results show that neuritic dystrophy is a prominent pathologic feature of the mThy1-α-syn tg model and suggest that CT α-syn might play an important role in the process of axonal damage in these mice as well as in DLB and PD...
  8. pmc Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy
    Leslie Crews
    Department of Pathology, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 5:e9313. 2010
    b>Lewy body disease is a heterogeneous group of neurodegenerative disorders characterized by alpha-synuclein accumulation that includes dementia with Lewy bodies (DLB) and Parkinson's Disease (PD)...
  9. pmc Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases
    Brian Spencer
    Department of Neurosciences, University of California, San Diego, La Jolla, California 92093 0624, USA
    J Neurosci 29:13578-88. 2009
    ..Accumulation of the synaptic protein alpha-synuclein (alpha-syn) is a hallmark of Parkinson's disease (PD) and Lewy body disease (LBD), a heterogeneous group of disorders with dementia and parkinsonism, where Alzheimer's disease and PD ..
  10. ncbi DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers
    C F Lippa
    Department of Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Neurology 68:812-9. 2007
    ....
  11. ncbi Visual perception in Parkinson disease dementia and dementia with Lewy bodies
    U P Mosimann
    Institute for Ageing and Health, Wolfson Research Centre, Newcastle General Hospital, Newcastle upon Tyne NE4 6BE, UK
    Neurology 63:2091-6. 2004
    ..To quantify visual discrimination, space-motion, and object-form perception in patients with Parkinson disease dementia (PDD), dementia with Lewy bodies (DLB), and Alzheimer disease (AD)...
  12. ncbi α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study
    Brit Mollenhauer
    Paracelsus Elena Klinik, Kassel, Germany
    Lancet Neurol 10:230-40. 2011
    ..We aimed to assess whether reduction of α-synuclein concentrations in CSF was a marker for α-synuclein deposition in the brain, and therefore diagnostic of synucleinopathies...
  13. ncbi Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders
    Petra E Spies
    Department of Geriatric Medicine, Radboud University Nijmegen Medical Centre, Donders Centre for Neuroscience, Nijmegen, The Netherlands
    J Alzheimers Dis 16:363-9. 2009
    ..We conclude that in clinically diagnosed patients, alpha-synuclein does not appear to be a useful biomarker for the differentiation between DLB and other types of dementia...
  14. ncbi Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease
    Hong Qing
    Kinsmen Laboratory of Neurological Research, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z3
    Biochem Biophys Res Commun 390:1229-34. 2009
    ..are the leading cause of genetically inherited Parkinson's disease (PD) and its more severe variant diffuse Lewy body disease (DLB). Pathological mutations in Lrrk2 are autosomal dominant, suggesting a gain of function...
  15. pmc Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease
    Eliezer Masliah
    Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 6:e19338. 2011
    ..These results suggest that passive immunization with monoclonal antibodies against the CT of α-syn may be of therapeutic relevance in patients with PD and DLB...
  16. pmc Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction
    Thomas G Beach
    Sun Health Research Institute, Sun City, AZ 85351, USA
    Acta Neuropathol 117:613-34. 2009
    ..autopsied subjects included elderly subjects with Parkinson's disease, dementia with Lewy bodies, incidental Lewy body disease and Alzheimer's disease with Lewy bodies, as well as comparison groups without Lewy bodies...
  17. ncbi Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters
    Edward Rockenstein
    Department of Neurosciences, University of California San Diego, La Jolla, California 92093 0624, USA
    J Neurosci Res 68:568-78. 2002
    Accumulation of alpha-synuclein has been associated with neurodegenerative disorders, such as Lewy body disease and multiple system atrophy...
  18. ncbi Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
    Annika Ohrfelt
    Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Molndal, Sweden
    Neurosci Lett 450:332-5. 2009
    ..The lower alpha-syn levels in AD, as well as the association of alpha-syn reduction with AD severity, approximated by MMSE, suggests that it may be a general marker of synapse loss, a hypothesis that warrants further investigation...
  19. ncbi A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease
    H L Melrose
    Molecular Genetics Laboratory and Core, Morris K Udall Parkinson s Disease Research Center of Excellence, Mayo Clinic, Department of Neuroscience, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Neuroscience 147:1047-58. 2007
    ..from wild type and human Lrrk2 transgenic bacterial artificial chromosome (BAC) mice, and from diffuse Lewy body disease (DLBD) patients...
  20. ncbi Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe
    A J Harding
    Prince of Wales Medical Research Institute and University of New South Wales, Barker Street, Sydney, NSW 2031, Australia
    Brain 125:391-403. 2002
    ..Thus, our results suggest that the distribution of temporal lobe LB is more related to the presence and duration of visual hallucinations in cases with LB than to the presence, severity or duration of dementia...
  21. pmc Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein
    J E Galvin
    Department of Neurology, Medical College of Pennsylvania, Hahnemann University, 245 North 15th Street, Philadelphia, PA 19129, USA
    Proc Natl Acad Sci U S A 96:13450-5. 1999
    ..Our findings broaden the concept of neurodegenerative "synucleinopathies" by implicating betaS and gammaS, in addition to alphaS, in the onset/progression of PD and DLB...
  22. ncbi Association of alpha-, beta-, and gamma-Synuclein with diffuse lewy body disease
    Kenya Nishioka
    Department of Neuroscience, Mayo Clinic Florida, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    Arch Neurol 67:970-5. 2010
    To determine the association of the genes that encode alpha-, beta-, and gamma-synuclein (SNCA, SNCB, and SNCG, respectively) with diffuse Lewy body disease (DLBD).
  23. pmc GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology
    Debby Tsuang
    Veterans Affairs Puget Sound Health Care System Seattle, WA, USA
    Neurology 79:1944-50. 2012
    ..Parkinson disease (PD) and are a well-established susceptibility factor for PD, which is characterized by Lewy body disease (LBD) neuropathologic changes (LBDNCs)...
  24. ncbi Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease
    P Ibanez
    INSERM U289, Neurologie et Thérapeutique Expérimentale, Hopital de la Pitie Salpetriere, AP HP, Paris, France
    Lancet 364:1169-71. 2004
    ..These results indicate that SNCA is more frequently associated with familial Parkinson's disease than previously thought, and that there is a clear dosage effect according to the number of supernumerary copies of this gene...
  25. pmc Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies
    Kejal Kantarci
    Departments of Radiology, Mayo Clinic, Rochester, MN, USA
    Neurology 79:553-60. 2012
    ..To determine the association between the focal atrophy measures on antemortem MRI and postmortem neuropathologic classification of dementia with Lewy bodies (DLB) using the Third Report of the DLB Consortium criteria...
  26. ncbi Differences in neuropathologic characteristics across the Lewy body dementia spectrum
    C Ballard
    Wolfson Centre for Age Related Diseases, Wolfson Building, Guy s Campus, King s College London, London, SE1 1UL, UK
    Neurology 67:1931-4. 2006
    ....
  27. pmc Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders
    Thomas G Beach
    Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ 85351, USA
    Acta Neuropathol 119:689-702. 2010
    ..tissue from 41 different sites in the bodies of 92 subjects, including 23 normal elderly, 7 with incidental Lewy body disease (ILBD), 17 with Parkinson's disease (PD), 9 with dementia with Lewy bodies (DLB), 19 with Alzheimer's ..
  28. ncbi Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Vienna, Austria
    Acta Neuropathol 115:427-36. 2008
    ....
  29. ncbi What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?
    Pietro Tiraboschi
    Dipartimento di Scienze Neurologiche, Ospedale Niguarda Ca Granda, Milano, Italy
    Brain 129:729-35. 2006
    ..This suggests that clinical history plus a brief assessment of visuospatial function may be of the greatest value in correctly identifying DLB early during the course of disease...
  30. ncbi Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study
    Ian McKeith
    Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne, UK
    Lancet Neurol 6:305-13. 2007
    ..Diagnostic accuracy, positive and negative predictive values, and inter-reader agreement were the secondary endpoints and a subgroup of possible DLB patients was also included...
  31. pmc Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy
    Malin Wennström
    Lund University, Department of Clinical Sciences Malmo, Molecular Memory Research Unit, The Wallenberg Laboratory at Skåne University Hospital, Malmo, Sweden
    PLoS ONE 8:e53250. 2013
    ....
  32. ncbi Change in perfusion, hallucinations and fluctuations in consciousness in dementia with Lewy bodies
    John T O'Brien
    Institute for Ageing and Health, University of Newcastle upon Tyne, Wolfson Research Centre, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK
    Psychiatry Res 139:79-88. 2005
    ..We have identified important neural correlates of key clinical features in Lewy body dementia and postulate that the associations can be understood through the influence of the cholinergic system on attention...
  33. ncbi Neuropathology of Lewy body disorders
    Eniko Kovari
    Department of Psychiatry, HUG Belle Idée, University Hospitals of Geneva, Switzerland
    Brain Res Bull 80:203-10. 2009
    ..The recent progress of neuropathology in this field made it possible to define clinical and neuropathological guidelines for the diagnosis. This review briefly describes the most important data of all Lewy body related disorders...
  34. ncbi Differences in clinical course between dementia with Lewy bodies and Alzheimer's disease
    H Hanyu
    Department of Geriatric Medicine, Tokyo Medical University, Tokyo, Japan
    Eur J Neurol 16:212-7. 2009
    ..To investigate whether there may be differences in the clinical course and changes in cognitive progression between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)...
  35. ncbi Serum and cerebrospinal fluid uric acid levels in lewy body disorders: associations with disease occurrence and amyloid-β pathway
    Walter Maetzler
    Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany
    J Alzheimers Dis 27:119-26. 2011
    ..Taken together, our results provide first evidence for disease-relevant but potentially distinct roles of UA in the blood and CSF compartment, respectively, in LBD...
  36. ncbi MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia
    R Barber
    Institute for the Health of the Elderly, Newcastle General Hospital, Newcastle upon Tyne, UK
    Neurology 54:1304-9. 2000
    ..To compare global and regional atrophy on MRI in subjects with dementia with Lewy bodies (DLB), AD, vascular dementia (VaD), and normal aging. In addition, the relationship between APOE-epsilon4 genotype and volumetric indices was examined...
  37. ncbi The CST3 BB genotype and low cystatin C cerebrospinal fluid levels are associated with dementia in Lewy body disease
    Walter Maetzler
    Department of Neurodegeneration, University of Tuebingen, Germany
    J Alzheimers Dis 19:937-42. 2010
    A large proportion of demented Lewy body disease patients have Alzheimer's disease (AD)- like pathology, in particular amyloid-beta (Abeta) plaques...
  38. ncbi Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease
    C Ballard
    Institute for the Health of the Elderly, Wolfson Research Centre, Newcastle General Hospital, Westgate Road, Newcastle, England NE4 6BE
    Arch Neurol 58:977-82. 2001
    ....
  39. ncbi Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease
    Satoshi Orimo
    Department of Neurology, Kanto Central Hospital, 6 25 1 Kami Yoga, Setagaya Ku, 158 8531, Tokyo, Japan
    Acta Neuropathol 109:583-8. 2005
    ..To elucidate the extent, frequency and pattern of cardiac sympathetic nerve involvement in Lewy body disease and related neurodegenerative disorders, we immunohistochemically examined heart tissues from patients with ..
  40. pmc Incidental Lewy body disease: clinical comparison to a control cohort
    Charles H Adler
    Parkinson s Disease and Movement Disorders Center, Mayo Clinic, Scottsdale, Arizona 85259, USA
    Mov Disord 25:642-6. 2010
    Limited clinical information has been published on cases pathologically diagnosed with incidental Lewy body disease (ILBD)...
  41. ncbi Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders
    E Masliah
    Department of Neurosciences, Department of Pathology, University of California San Diego, La Jolla, CA 92093 0624, USA
    Science 287:1265-9. 2000
    ..These results suggest that accumulation of wild-type alpha-synuclein may play a causal role in Parkinson's disease and related conditions...
  42. ncbi CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease
    Moeko Noguchi-Shinohara
    Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
    Brain Res 1251:1-6. 2009
    ..However, the lower alpha-synuclein levels in DLB patients with longer duration suggest a reduction in CSF alpha-synuclein in association with increased severity of alpha-synucleinopathy in the brain...
  43. pmc Beta-synuclein gene alterations in dementia with Lewy bodies
    H Ohtake
    Department of Neurology, Brain Research Institute, Niigata University, Niigata, Japan
    Neurology 63:805-11. 2004
    ..To determine whether mutations in the genes for alpha-synuclein or beta-synuclein are responsible for dementia with Lewy bodies (DLB), a disorder closely related to Parkinson disease (PD)...
  44. ncbi S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function
    Kenny K K Chung
    Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Science 304:1328-31. 2004
    ..in vitro, as well as in vivo in a mouse model of PD and in brains of patients with PD and diffuse Lewy body disease. Moreover, S-nitrosylation inhibits parkin's ubiquitin E3 ligase activity and its protective function...
  45. ncbi Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization
    Daryl A Bosco
    Department of Chemistry and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, California 92037, USA
    Nat Chem Biol 2:249-53. 2006
    ..By extension, these data lead to the hypothesis that oxidative stress produces cholesterol aldehydes that enable alpha-synuclein aggregation, leading to a pathologic cycle...
  46. ncbi A clinico-pathological study of subtypes in Parkinson's disease
    M Selikhova
    Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College, London, UK
    Brain 132:2947-57. 2009
    ..047). An analysis of cases with pathologically defined neocortical Lewy body disease confirmed the link between bradykinetic onset, cognitive decline and Lewy body deposition in the neocortex...
  47. ncbi EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up
    Laura Bonanni
    Department of Neurology, Aging Research Center, Ce S I, Gabriele D Annunzio University Foundation, University G d Annunzio of Chieti Pescara, via Fonte Romana, 65124 Pescara, Italy
    Brain 131:690-705. 2008
    ....
  48. ncbi Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study
    David R Williams
    Queen Square Brain Bank for Neurological Disorders and Institute of Neurology, University College London, London, UK
    Lancet Neurol 4:605-10. 2005
    ..The cause of VH is now thought to be nerve-cell loss and Lewy-body pathology in the ventral-temporal regions of the brain. However, the use of VH as a clinical sign of PD has not been investigated...
  49. ncbi Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET
    H Shimada
    Molecular Neuroimaging Group, Molecular Imaging Center, National Institute of Radiological Sciences, 4 9 1 Anagawa, Inage Ku, Chiba shi, Chiba 260 8555, Japan
    Neurology 73:273-8. 2009
    ..To characterize brain cholinergic deficits in Parkinson disease (PD), PD with dementia (PDD), and dementia with Lewy bodies (DLB)...
  50. ncbi A critical reappraisal of current staging of Lewy-related pathology in human brain
    Kurt A Jellinger
    Institute of Clinical Neurobiology, Kenyongasse 18, 1070, Vienna, Austria
    Acta Neuropathol 116:1-16. 2008
    ....
  51. pmc Emerging pathways in genetic Parkinson's disease: Potential role of ceramide metabolism in Lewy body disease
    Jose Bras
    Molecular Genetics Unit, National Institutes on Aging, Bethesda, MD, USA
    FEBS J 275:5767-73. 2008
    ..mutations at the glucosecerebrosidase locus have recently been shown to be a potent risk factor for Lewy body disease. Based on this observation, we have re-evaluated the likelihood that the different PARK loci (defined using ..
  52. ncbi Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease
    Dennis W Dickson
    Neuropathology Laboratory, Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA
    Acta Neuropathol 115:437-44. 2008
    ..When Lewy bodies are found in normal individuals, the process is sometimes referred to as incidental Lewy body disease (iLBD)...
  53. ncbi Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis
    E J Burton
    Wolfson Research Centre, Institute for Ageing and Health, Newcastle University, Campus for Ageing and Vitality, Newcastle upon Tyne, UK
    Brain 132:195-203. 2009
    ..Pathologically, it is more strongly related to tangle rather than plaque or Lewy body pathology in the temporal lobe. It may have utility as a means for stratifying samples in vivo on the basis of putative differences in pathology...
  54. ncbi Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies
    Katerina E Paleologou
    Division of Biomedical and Life Sciences, School of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK
    Brain 132:1093-101. 2009
    ..Furthermore, these findings establish FILA-1 as a very sensitive tool for the detection of oligomeric forms of alpha-syn in human brain lysates...
  55. ncbi Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity?
    Dag Aarsland
    Psychiatric Clinic, Rogaland Central Hospital, PO Box 1163, Hillevaag, 4095 Stavanger, Norway
    J Geriatr Psychiatry Neurol 17:137-45. 2004
    ....
  56. ncbi Why people see things that are not there: a novel Perception and Attention Deficit model for recurrent complex visual hallucinations
    Daniel Collerton
    South of Tyne and Wearside Mental Health NHS Trust, Bensham Hospital, Gateshead NE8 4YL, United Kingdom
    Behav Brain Sci 28:737-57; discussion 757-94. 2005
    ..Several tests of the model are indicated, together with a number of treatment options that it generates...
  57. ncbi A comparison of (99m)Tc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer's disease using statistical parametric mapping
    Sean J Colloby
    Wolfson Research Centre, The Institute for Ageing and Health, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, NE4 6BE, UK
    Eur J Nucl Med Mol Imaging 29:615-22. 2002
    ..In conclusion, we found evidence of frontal and parietal hypoperfusion in both AD and DLB, while temporal perfusion deficits were observed exclusively in AD and parieto-occipital deficits in DLB...
  58. ncbi Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial
    Dag Aarsland
    The Norwegian Centre for Movement Disorders, Stavanger University Hospital, 4068 Stavanger, Norway
    Lancet Neurol 8:613-8. 2009
    ..We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine in patients with PDD or DLB...
  59. ncbi CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease
    Fransje E Reesink
    Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
    J Alzheimers Dis 22:87-95. 2010
    ..05). Ultimately, CSF α-synuclein was not a useful diagnostic biomarker to differentiate DLB and/or PD (α-synucleinopathies) from AD or SC. In DLB patients maybe lower CSF α-synuclein levels are related to worse cognitive performance...
  60. pmc Visual hallucinations in dementia with Lewy bodies: transcranial magnetic stimulation study
    John Paul Taylor
    Institute for Ageing and Health, Newcastle University, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5PL, UK
    Br J Psychiatry 199:492-500. 2011
    ..The aetiology of visual hallucinations is poorly understood in dementia with Lewy bodies. Pathological alterations in visual cortical excitability may be one contributory mechanism...
  61. ncbi Thalamic D2 receptors in dementia with Lewy bodies, Parkinson's disease, and Parkinson's disease dementia
    Margaret A Piggott
    IAH Research Laboratories, Institute for Ageing and Health, University of Newcastle upon Tyne, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne, UK
    Int J Neuropsychopharmacol 10:231-44. 2007
    ..D2 receptor binding did not vary with cognitive decline (MMSE) or visual hallucinations, but was significantly higher with increased extrapyramidal symptoms...
  62. ncbi Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease
    Katrin Beyer
    Department of Pathology, Hospital Germans Trias i Pujol, Autonomous University of Barcelona, Barcelona, Spain
    Neurogenetics 9:163-72. 2008
    ..In conclusion, isoform-expression profiles in LB diseases represent additional evidence for the direct involvement of isoform-expression deregulation in the development of neurodegenerative disorders...
  63. ncbi Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial
    Murat Emre
    Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
    Lancet Neurol 9:969-77. 2010
    ..Therefore, the efficacy and safety of memantine were investigated in patients with mild to moderate Parkinson's disease dementia (PDD) or dementia with Lewy bodies (DLB)...
  64. ncbi CSF and clinical hallmarks of subcortical dementias: focus on DLB and PDD
    Alessandro Stefani
    Dipartimento di Neuroscienze, Universita di Roma Tor Vergata, Rome, Italy
    J Neural Transm 119:861-75. 2012
    ..However, more complete data, possibly collected in fieri during the progressive derangement of cognitive abilities, are needed to improve our ability to decipher and treat these entities...
  65. ncbi Levodopa response in dementia with lewy bodies: a 1-year follow-up study
    Claudio Lucetti
    Neurology Unit, Hospital of Viareggio, Italy
    Parkinsonism Relat Disord 16:522-6. 2010
    ..To evaluate levodopa responsiveness in patients with probable dementia with Lewy bodies (DLB) compared to early Parkinson's disease (PD) patients...
  66. ncbi Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry
    E J Burton
    Institute for Ageing and Health, University of Newcastle upon Tyne, United Kingdom
    Neuroimage 17:618-30. 2002
    ..Comparison of dementia groups showed preservation of the medial temporal lobe, hippocampus, and amygdala in DLB relative to AD. Significant gray matter loss was also observed in the thalamus of AD patients compared to DLB...
  67. pmc Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease
    J E Galvin
    Center of Excellence on Brain Aging, New York University Langone School of Medicine, 145 East 32nd St, Second Floor, New York, NY 10016, USA
    Neurology 76:1797-803. 2011
    ..We performed resting state blood oxygen level-dependent (BOLD) functional connectivity MRI (fcMRI) to determine whether there were differences between AD and DLB...
  68. pmc Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease
    Marzena Kurzawa-Akanbi
    Medical Toxicology Centre, Wolfson Building, Newcastle University, Newcastle upon Tyne, UK
    J Neurochem 123:298-309. 2012
    b>Lewy body disease (LBD) development is enhanced by mutations in the GBA gene coding for glucocerebrosidase (GCase)...
  69. ncbi Early diagnosis of dementia
    K S SantaCruz
    University of Kansas Medical Center, Kansas City, USA
    Am Fam Physician 63:703-13, 717-8. 2001
    ..Follow-up by the patient's family physician is appropriate in most patients. However, a subspecialist may be helpful in the diagnosis and management of patients with dementia with an unusual presentation or following an atypical course...
  70. ncbi Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease
    Yuichi Fumimura
    Department of Neuropathology, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
    J Neuropathol Exp Neurol 66:354-62. 2007
    b>Lewy body disease is defined as Lewy body-related neuronal degeneration involving the nigrostriatal system, limbic-neocortical system, and peripheral autonomic nervous system (PANS)...
  71. pmc Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease
    Michael T Lin
    Department of Neurology and Neuroscience, Weill Cornell Medical College, New York, NY, USA
    Ann Neurol 71:850-4. 2012
    ..To address this issue, we studied early stage PD cases and cases of incidental Lewy body disease (ILBD), which is thought to represent presymptomatic PD...
  72. ncbi Enhanced accumulation of phosphorylated alpha-synuclein and elevated beta-amyloid 42/40 ratio caused by expression of the presenilin-1 deltaT440 mutant associated with familial Lewy body disease and variant Alzheimer's disease
    Hiroyuki Kaneko
    Department of Molecular Neuroscience, Center for Bioresources, Niigata University, Niigata 951 8585, Japan
    J Neurosci 27:13092-7. 2007
    ....
  73. pmc Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders
    Ozlem Goker-Alpan
    Section on Molecular Neurogenetics, Medical Genetics Branch, NHGRI, National Institutes of Health, Bethesda, MD 20892 3708, USA
    Acta Neuropathol 120:641-9. 2010
    ..Unraveling the role of mutant glucocerebrosidase in the development of this pathology will further our understanding of the lysosomal pathways that likely contribute to the formation and/or clearance of these protein aggregates...
  74. pmc Coexistent Lewy body disease in a case of "visual variant of Alzheimer's disease"
    D F Tang-Wai
    J Neurol Neurosurg Psychiatry 74:389. 2003
  75. ncbi The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease
    C Ballard
    Institute of Health for the Elderly, Newcastle General Hospital, Newcastle upon Tyne, UK
    Int J Geriatr Psychiatry 16:494-8. 2001
    ..CONCLUSIONS: Although attention is the cognitive domain which fluctuates most markedly, other cognitive domains are also affected. FC also has a significant independent impact on activities of daily living...
  76. ncbi Rapidly progressive diffuse Lewy body disease
    Carles Gaig
    Neurology Service, Hospital Clinic of Barcelona, Barcelona, Spain
    Mov Disord 26:1316-23. 2011
    ..Lewy body syndromes (mainly Parkinson's disease and dementia with Lewy bodies) share many clinical features and usually have a slowly progressive course. Some patients may show rapid symptoms progression...
  77. ncbi The influence of vascular risk factors on the survival rate of patients with dementia with Lewy bodies and Alzheimer disease
    Radosław Magierski
    Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Poland
    Neurol Neurochir Pol 44:139-47. 2010
    ..The aim of this study was to determine whether dementia with Lewy bodies (DLB) progres-ses more rapidly than Alzheimer disease (AD) and to compare survival after dementia onset and mortality in both dementia groups...
  78. ncbi Efficacy and safety of donepezil in patients with dementia with Lewy bodies: preliminary findings from an open-label study
    Satoru Mori
    Department of Neurology, Matsushita Memorial Hospital, Moriguchi, Osaka, Japan
    Psychiatry Clin Neurosci 60:190-5. 2006
    ....
  79. ncbi Autonomic dysfunction in dementia with Lewy bodies
    P Thaisetthawatkul
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    Neurology 62:1804-9. 2004
    ..To assess autonomic function in patients with dementia with Lewy bodies (DLB)...
  80. pmc The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations
    Ozlem Goker-Alpan
    Section on Molecular Neurogenetics, National Human Genome Research Institute, National Institutes of Health, 35 Convent Dr, MSC 3708, Bldg 35, Room 1A213, Bethesda, MD 20892 3708, USA
    Arch Neurol 65:1353-7. 2008
    ..Mutations in the glucocerebrosidase gene (GBA) result in Gaucher disease and can be associated with a phenotype characterized by adult-onset progressive neurologic deterioration and parkinsonism...
  81. ncbi Patients with dementia with lewy bodies have more impaired quality of life than patients with Alzheimer disease
    Fredrik Bostrom
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo University Hospital, Lund University, Malmo, Sweden
    Alzheimer Dis Assoc Disord 21:150-4. 2007
    ....
  82. ncbi Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease
    Kunikazu Tanji
    Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, 5 Zaifu cho, Hirosaki 036 8562, Japan
    Neurobiol Dis 43:690-7. 2011
    ..In this study, we determined whether Atg8 homologues are affected in Lewy body disease, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB)...
  83. ncbi Glucocerebrosidase mutations confer a greater risk of dementia during Parkinson's disease course
    Núria Setó-Salvia
    Neurology Department Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain
    Mov Disord 27:393-9. 2012
    ....
  84. ncbi Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies
    Mona K Beyer
    Department of Radiology, Stavanger University Hospital, Stavanger, Norway
    Neurology 69:747-54. 2007
    ..We conducted a study using voxel-based morphometry (VBM) to explore the pattern of cortical atrophy in DLB and PDD...
  85. ncbi Neprilysin activity in cerebrospinal fluid is associated with dementia and amyloid-β42 levels in Lewy body disease
    Walter Maetzler
    Center of Neurology, Department of Neurodegeneration, Hertie Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany
    J Alzheimers Dis 22:933-8. 2010
    b>Lewy body disease, defined by the occurrence of α-synuclein aggregates as fibrils in Lewy bodies and Lewy neurites, is associated with increased probabilities for both co-occurrence of dementia, and co-occurrence of Alzheimer's disease (..
  86. ncbi The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease
    C Ballard
    Reader in Old Age Psychiatry, University of Newcastle, Newcastle General Hospital, Newcastle upon Tyne, UK
    Int J Geriatr Psychiatry 16:499-503. 2001
    ..Little is known about the rate of progression or associations of cognitive impairment in dementia with Lewy bodies (DLB), or the associations of accelerated decline...
  87. ncbi Cerebral metabolic dysfunction in patients with dementia with Lewy bodies and visual hallucinations
    Robert Perneczky
    Department of Psychiatry and Psychotherapy, Technical University Munich, Munich, Germany
    Dement Geriatr Cogn Disord 25:531-8. 2008
    ..To identify the pattern of cerebral hypometabolism in patients with dementia with Lewy bodies (DLB) and visual hallucinations (VH)...
  88. ncbi Glucocerebrosidase mutations are an important risk factor for Lewy body disorders
    O Goker-Alpan
    Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, NIH, Bethesda, MD 20892 3708, USA
    Neurology 67:908-10. 2006
    ..Mutations in this lysosomal protein may interfere with the clearance or promote aggregation of alpha-synuclein...
  89. ncbi The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies
    M Andersson
    Neuropsychiatric Clinic, Malmo University Hospital, Malmo, Sweden
    Int J Geriatr Psychiatry 23:192-8. 2008
    ....
  90. ncbi Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodies
    Ryoko Yamamoto
    Department of Psychiatry, Juntendo Tokyo Koto Geriatric Medical Center, Juntendo University School of Medicine, 3 3 20 Shinsuna, Koto ku, Tokyo 136 0075, Japan
    J Neurol Sci 246:95-101. 2006
    ..In addition, we compared Lewy pathology between cases with and without visual hallucinations, and showed no significant differences between the two groups...
  91. ncbi Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics
    Walter Maetzler
    Center of Neurology, Department of Neurodegeneration and Hertie Institute for Clinical Brain Research, University of Tuebingen, Germany
    Neurobiol Dis 34:107-12. 2009
    About one fourth of Lewy body disease (LBD) patients show cortical beta-amyloid load, basically a hallmark of Alzheimer disease (AD)...
  92. pmc Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy--implications for excitotoxicity
    Diana L Price
    Department of Neurosciences, University of California San Diego, La Jolla, California, United States of America
    PLoS ONE 5:e14020. 2010
    ..These results highlight the therapeutic importance of mGluR5 antagonists in alpha-synucleinopathies...
  93. ncbi Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD
    K Lobotesis
    Institute for the Health of the Elderly, Newcastle General Hospital, Newcastle upon Tyne, UK
    Neurology 56:643-9. 2001
    ..Although not diagnostically specific in individual cases, occipital hypoperfusion on SPECT should raise suspicion that DLB may be the cause of dementia, prompting careful search for other features of the disorder...
  94. ncbi Using the presence of visual hallucinations to differentiate Parkinson's disease from atypical parkinsonism
    D R Williams
    Faculty of Medicine, Neurosciences, Monash University, Alfred Hospital Campus, Commercial Rd, Melbourne 3004, Australia
    J Neurol Neurosurg Psychiatry 79:652-5. 2008
    ..To address the issue of diagnosis in patients with parkinsonism, we developed instructions for a structured interview (Queen Square Visual Hallucination Inventory (QSVHI)), capable of rapidly screening for VH in the outpatient setting...
  95. ncbi Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB
    T Mori
    Department of Neuropsychiatry, Ehime University School of Medicine, Ehime, Japan
    Neurology 66:935-7. 2006
    ..Hallucinations attenuated while receiving therapy, whereas occipital rCBF focally increased, suggesting that functional visual association cortex deficits may cause visual hallucinations in patients with DLB...
  96. ncbi Glucocerebrosidase mutations in diffuse Lewy body disease
    Kenya Nishioka
    Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
    Parkinsonism Relat Disord 17:55-7. 2011
    ..8% (4/59) of cases with a pathological diagnosis of diffuse Lewy body disease. Taken with previous studies, it appears that GBA mutations are associated with a more diffuse pattern of ..
  97. ncbi Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies
    Jacques Pasquier
    Departement de Medecine Nucleaire, Institut Paoli Calmettes, Universite de la Mediterranee, 232 Boulevard Sainte Marguerite, BP 156, 13273 Marseille Cedex 9, France
    Eur J Nucl Med Mol Imaging 29:1342-8. 2002
    ..The findings also support a link between visual hallucinations and structural/functional changes in the occipital region in DLB patients...
  98. ncbi Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer's disease (AD)
    Monica Ricci
    Regina Apostolorum Hospital, Albano Laziale, Italy
    Arch Gerontol Geriatr 49:e101-4. 2009
    ..DLB subjects have a different neuropsychological profile, more psychiatric symptoms and more serious functional deficits than AD subjects in the early cognitive decline, furthermore DLB caregivers are more stressed than AD caregivers...
  99. ncbi Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia
    Cristina Sanchez-Castaneda
    Dementia Unit, Department of Neurology, Bellvitge University Hospital, Barcelona, Spain
    Mov Disord 25:615-22. 2010
    ..The patterns of structural and functional correlations were different in both pathologies...
  100. ncbi Usefulness of a blood flow analyzing program 3DSRT to detect occipital hypoperfusion in dementia with Lewy bodies
    Masaru Tateno
    Department of Neuropsychiatry, Sapporo Medical University, Sapporo, Japan
    Prog Neuropsychopharmacol Biol Psychiatry 32:1206-9. 2008
    ..The quantitative analysis of brain perfusion SPECT by 3DSRT could be a useful supportive measurement in the diagnosis of DLB...
  101. ncbi Clinical and neuropathological correlates of apolipoprotein E genotype in dementia with Lewy bodies
    Andrew B Singleton
    Medical Research Council University of Newcastle upon Tyne, Centre Development in Clinical Brain Ageing, MRC Building, Newcastle upon Tyne, UK
    Dement Geriatr Cogn Disord 14:167-75. 2002
    ..This study demonstrates that DLB shares the APO epsilon4 allele with AD as a common risk factor, but that there are differences in the way the epsilon4 allele affects the phenotypic expression of disease...

Research Grants62

  1. Exploring the Role of the Brain Epigenome: Cognitive Decline and Life Experiences
    David Alan Bennett; Fiscal Year: 2013
    ..e., Alzheimer's disease, cerebrovascular disease, and Lewy body disease), these conditions only account for about 20% of the variance of cognition in older persons...
  2. Radiolabled MAO-B Substrates for Imaging
    Michael R Kilbourn; Fiscal Year: 2012
    ..epilepsy), differentiation of related diseases (Alzheimer's versus frontal-temporal dementia (FTD) or Lewy Body disease), and evaluation of new therapeutic treatments, and thus could significantly assist in the diagnosis and ..
  3. Cognitive Decline and Dementia: Life Experiences and the Brain Histone Epigenome
    David A Bennett; Fiscal Year: 2010
    ..in old age often results from one or more of three common brain diseases, AD, cerebrovascular disease, and Lewy body disease, these conditions only account for about 20% of the variance of cognition in older persons...
  4. Role of impaired cognitive states &risk factors in conversion to mixed dementias
    Lei Yu; Fiscal Year: 2013
    ..Alzheimer's disease (AD) from other prevalent brain diseases that include vascular dementia (VaD) and Lewy body disease (LBD)...
  5. A Novel Ubiquitin-Dependent Pathogenic Pathway in Spongiform Neurodegeneration
    Lih Shen Chin; Fiscal Year: 2013
    ..this pathology is also present in the brains of patients suffering from Alzheimer's disease, diffuse Lewy body disease, and acquired immune deficiency syndrome (AIDS)...
  6. Development of a Plasma Biomarker of Alzheimer's Disease
    MARK ANTHONY LOVELL; Fiscal Year: 2012
    ..analyzed from subjects with non-AD neurodegenerative diseases including frontotemporal dementia and diffuse Lewy body disease. In addition, we will test whether pre-conversion PDS/TTR concentrations alone, or in combination with A[..
  7. Progranulin interaction with Sortilin in FrontoTemporal Dementia
    Stephen M Strittmatter; Fiscal Year: 2013
    ..dementia (FTD) is the third most common cause of neurodegenerative dementia, after AD and Diffuse Lewy Body Disease. The clinical features of FTD include memory deficits, behavioral abnormalities, personality changes and ..
  8. Therapeutic Targeting of Abnormal Conformation in Neurodegenerative Disease
    Thomas M Wisniewski; Fiscal Year: 2013
    ..AD) is the most common of the neurodegenerative protein conformational disorders, which include diffuse Lewy body disease (DLBD), Parkinson's disease (PD), prion diseases, and frontotemporal lobar degeneration (FTLD)...
  9. Molecular Genetic Analysis of Lysosomal Storage Disorder Genes in PD
    Lorraine N Clark; Fiscal Year: 2011
    ..R21, NS050487, we have shown that mutations in the glucocerebrosidase gene are risk factors for PD and Lewy body disease. In the current application we propose to continue our studies on the GBA gene and will examine three ..
  10. a-synuclein clearance strategies for the treatment of Lewy body disease
    Eliezer Masliah; Fiscal Year: 2013
    b>Lewy body disease (LBD) is a group of disorders characterized by alpha-synuclein (alpha-syn) accumulation and parkinsonism...
  11. Pathological basis of MRS and DTI changes in neurodegenerative dementia
    Kejal Kantarci; Fiscal Year: 2013
    ..cognitive decline, mild cognitive impairment (MCI) and dementia are Alzheimer's disease (AD) and Lewy body disease (LBD) pathologies...
  12. National Brain and Tissue Resource for Parkinson's Disease and Related Disorders
    Thomas G Beach; Fiscal Year: 2013
    ..by applicant): Parkinson's disease (PD) and related Lewy body disorders (LBD), including incidental Lewy body disease (ILDB), Alzheimer's disease with Lewy bodies (ADLB) and dementia with Lewy bodies (DLB) may affect up ..
  13. Varian 4 Tesla MRI/MRS for Neuro-degenerative Diseases
    Michael Weiner; Fiscal Year: 2002
    ..have funded projects on normal aging, Alzheimer's disease, frontotemporal dementia, vascular dementia, Lewy Body disease, epilepsy, Parkinson's disease, amyotrophic lateral sclerosis, post traumatic stress disorder, schizophrenia,..
  14. EMISSION COMPUTED TOMOGRAPHY OF LOCAL CEREBRAL FUNCTION
    David Kuhl; Fiscal Year: 2001
    ..have the premortem clinical criteria and neuro-psychological profile which have been attributed to Diffuse Lewy Body Disease (DLBD)...
  15. Alpha-Synuclein: A Drug Target for Parkinson's Disease
    Michael Lebowitz; Fiscal Year: 2001
    ..that act as a-synuclein oligomerization inhibitors, and begin pre-clinical testing of both the small molecule and peptide-based drug candidates in animal models of Lewy body disease. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
  16. DEMENTIA WITH PARKINSONISM: WHAT ARE WE DIAGNOSING?
    Carol Lippa; Fiscal Year: 1999
    ..The more recently recognized Lewy body disease (LBD), as a presumptive third entity, may also produce a clinical and pathological syndrome that can ..
  17. NEUROPSYCHOLOGY OF DEMENTIA WITH LEWY BODIES
    TANIS FERMAN; Fiscal Year: 2009
    ..This has implications for symptom management, development of treatment options and for providing education and support to DLB patients and their caregivers. ..
  18. Dementia of Parkinson Type: Clinicopathologic Phenotype
    James Galvin; Fiscal Year: 2004
    ..At the completion of the award period, candidate plans to develop an independent R01 project derived from the data generated by the experiments described in this proposal. ..
  19. BASIS OF SYNAPTIC PATHOLOGY IN ALZHEIMERS DISEASE
    Eliezer Masliah; Fiscal Year: 2001
    ..These studies will help to better understand the mechanisms of synaptic pathology in AD and to develop potential neuroprotective agents that will operate by enhancing the GT activity. ..
  20. Visual Cognition in Dementia with Lewy Bodies
    Joanne M Hamilton; Fiscal Year: 2010
    ....
  21. Study on Thalidomide as BACE1 inhibitor in Alzhiemer's disease
    Marwan N Sabbagh; Fiscal Year: 2010
    ..We propose that Thalidomide may represent a BACE1 inhibitor. ..
  22. AMYLOIDOGENIC EFFECTS OF CHOLINERGIC DENERVATION
    Thomas Beach; Fiscal Year: 2002
    ..This could lead to impaired cerebral vasoregulation and increased susceptibility to ischemia, further compromising cortical function in AD. ..
  23. B-Synuclein as a Treatment for Lewy Body Disease
    Eliezer Masliah; Fiscal Year: 2005
    The new title of this revised application: "beta- synuclein as a treatment for Lewy body disease" reflects the modified and sharper focus on our scientific approach in response to the reviewers' major concern that synuclein might be more ..
  24. Implementation of [18F] FEOBV for VAChT Imaging with PET
    Robert Koeppe; Fiscal Year: 2004
    ..g. AD). R33 (Year 5): Conclude clinical evaluations in normal control and patient groups. ..
  25. Pioglitazone in Alzheimer's Disease Progression
    David Geldmacher; Fiscal Year: 2003
    ..Comparison of mean differences (using last observation carried forward imputation techniques) and survival analyses will be employed to assess for group differences in clinical measures AD of progression. ..
  26. Sleep, Circadian Rhythms and Dementing Illnesses
    David Harper; Fiscal Year: 2007
    ..in the etiology of sleep-wake disturbance in Alzheimer's disease, frontotemporal degeneration, and Lewy body disease. In addition, we have found abnormalities in SCN cellular populations in men linked with specific circadian ..
  27. Risk Factors and the Neurobiologic Substrate of Frailty
    Aron Buchman; Fiscal Year: 2009
    ..abstract_text> ..
  28. DEPRESSION DIAGNOSIS AND TREATMENT IN PARKINSON DISEASE
    Daniel Weintraub; Fiscal Year: 2008
    ..abstract_text> ..
  29. Biomarkers in Aging, MCI and Alzheimer's Disease
    Douglas Galasko; Fiscal Year: 2007
    ..Banked CSF and plasma will be available for further research into novel biomarkers, including broad-based proteomic studies. ..
  30. AGE RELATED NEURODEGENERATIVE DISEASES IN MICRONESIA
    Douglas Galasko; Fiscal Year: 2006
    ..Subproject by Lee: 'PHF-tau in neurodegenerative diseases of Guam' will assess oxidative markers related to brain lesions in ALS, PDC and dementia. ..
  31. Conference on the Diagnosis of Multiple System Atrophy
    Sid Gilman; Fiscal Year: 2006
    ..This conference will assist with early diagnosis by developing new guidelines for diagnosis using newly available imaging and neuropathological criteria. [unreadable] [unreadable] [unreadable]..
  32. Sleep/Wake Contiuum in Lewy Body Disease
    Donald L Bliwise; Fiscal Year: 2010
    ..The proposed work will also provide important clinical insights into disease correlates and disease course across the broad spectrum of Parkinsonism. ..
  33. Genetic Analysis of Tau H1 in Parkinsonism
    Matthew Farrer; Fiscal Year: 2006
    ..abstract_text> ..
  34. In vivo mapping of gray matter loss in preclinical AD
    Satoshi Minoshima; Fiscal Year: 2007
    ..If very early involvement of the posterior cingulate and association cortices are found consistently, these findings will provide better markers for early detection of the disease and monitoring of disease progression. ..
  35. Sleep Disordered Breathing, APOE and Lipid Metabolism
    Emmanuel Mignot; Fiscal Year: 2005
    ..With lipid metabolism being critical to cardiovascular risk, this application will also trigger further studies focusing on cardiovascular impact with adequate control of SDB. ..
  36. dementias of the Alzheimer's Type
    George Martin; Fiscal Year: 2005
    ..abstract_text> ..
  37. LIPID PEROXIDATION, TOXICANTS, AND MITOCHONDRIA
    MATTHEW PICKLO; Fiscal Year: 2003
    ..With this knowledge, novel therapeutic interventions or preventative strategies may be designed for these diseases. ..
  38. SUNDOWN SYNDROME IN A SKILLED NURSING FACILITY
    Donald Bliwise; Fiscal Year: 2002
    ..These results will provide information on the mechanistic basis for sundowning in aged patients with dementing disorders. ..
  39. Mechanisms of amyloid-beta clearance.
    Brian Bacskai; Fiscal Year: 2006
    ..The results will strongly impact the development of treatments aimed at removing senile plaques and the associated neurological damage in Alzheimer's disease. ..
  40. SLEEP HOMEOSTASIS AND STIMULANT DRUGS OF ABUSE
    Emmanuel Mignot; Fiscal Year: 2002
    ....
  41. Circuitry of Midbrain Dopamine in Sleep & Wake
    David Rye; Fiscal Year: 2005
    ..g., schizophrenia) and hypodopaminergic (e.g., PD and restless legs/periodic leg movements of sleep). ..
  42. Novel Pathways of HAARTmediated Neuronal Toxicity in the Central Nervous System
    Kelly L Jordan Sciutto; Fiscal Year: 2010
    ..abstract_text> ..
  43. White Matter Change and CNS Process in the Elderly
    Lisa Silbert; Fiscal Year: 2008
    ..This application proposes a structured didactic mentorship program for the principal investigator, Dr. Lisa Silbert, to ensure her independence as a clinical investigator at the end of the 5-year award period. [unreadable] [unreadable]..
  44. Predictors of Alzheimers Disease in Mild Cognitive Impairment
    Oscar Lopez; Fiscal Year: 2007
    ..g., structural and perfusion MRI, plasma beta-amyloid) and the factors that modify the risk to express the clinical syndrome takes on an added importance. [unreadable] [unreadable] [unreadable] [unreadable]..
  45. Neuroprotective Effects of Enhanced Proteasome Function
    BARBARA SNIDER; Fiscal Year: 2006
    ....
  46. Role of Hypocretin in Metabolic Effects of Sleep Loss
    Emmanuel Mignot; Fiscal Year: 2008
    ..These studies will be critical to extend our understanding of the association between chronic sleep loss, metabolism and body weight regulation. ..
  47. Predicting Driver Safety in Parkinson's Disease
    Ergun Uc; Fiscal Year: 2007
    ..Fair and accurate means of detecting unfit drivers with PD will help mitigate the tragedy of motor vehicle crashes caused by these impaired individuals. ..
  48. VAS-COG 2007
    Donald Royall; Fiscal Year: 2007
    ..Many vascular cognitive disorders are preventable and potentially reversible. VAS-COG will provide a forum in which information on these important conditions can be exchanged and disseminated. [unreadable] [unreadable] [unreadable]..
  49. Anti-oxidant therapy in Alzheimer's disease
    Brian J Bacskai; Fiscal Year: 2010
    ..abstract_text> ..
  50. PET IN HYPERKINETIC DISORDERS--A MULTICENTER STUDY
    David Eidelberg; Fiscal Year: 2001
    ..This approach may have great utility in evaluating new interventions for the treatment of the hyperkinetic movement disorders. ..
  51. BRAINSTEM SUBSTRATES OF DOPAMINE MODULATED MOVEMENTS
    David Rye; Fiscal Year: 2002
    ..g., OCD, ADD, Tourette's and schizophrenia, the results will also bear relevance to a wider spectrum of disease. ..
  52. Aging Brain: DTI, Subcortical Ischemia and Behavioral
    Stephen Salloway; Fiscal Year: 2006
    ..abstract_text> ..
  53. ROLE OF PROTEASOMAL DYSFUNCTION IN PARKINSON'S DISEASE
    KEVIN MCNAUGHT; Fiscal Year: 2008
    ..These studies will test our hypothesis that inadequate proteasomal function underlies both vulnerability and degeneration of the SNc in sporadic Parkinson's disease. ..
  54. COMPARING THREE ELECTRODE PLACEMENTS TO OPTIMIZE ECT
    Keith Rasmussen; Fiscal Year: 2005
    ..The results of this study will promote more effective and safer treatment of the most severely ill depressed patients. ..
  55. ENERGY METABOLISM, DOPAMINE NEURONS AND NEUROTOXICITY
    Gail Zeevalk; Fiscal Year: 2008
    ..The studies will have relevance to neurodegenerative conditions or pathophysiological situations in which metabolism is compromised. ..
  56. Seeking the Biomarkers of Aging and Diseases of Aging conference
    George Martin; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  57. Second International Brainstorming Meeting on Parkinson Disease: Nosology
    Irene Litvan; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  58. Frontotemporal degeneration: a basis for clinical trials
    David Knopman; Fiscal Year: 2006
    ..abstract_text> ..
  59. PANDAS and Strep Infection: Are they Linked?
    Roger Kurlan; Fiscal Year: 2004
    ..Disproving the PANDAS hypothesis would prevent the use of expensive and potentially dangerous therapies (e.g., plasma exchange, immune globulin, antibiotics) that have been proposed for PANDAS patients. ..